Alcon's fiscal second quarter arrived with the company two and a half years into its largest single bet in surgery: the PowerVision intraocular lens program, acquired for roughly a billion dollars in 2019 and pitched as the next step beyond the standard lenses surgeons already trust. That bet is now over. In August, after the latest clinical data still showed persistent, unpredictable post-surgical visual outcomes in a subset of patients, management discontinued the program and took a $505 million impairment - the whole carrying value of the asset - booked retroactively into the June quarter. Strip out that non-cash charge and the report is a different story entirely. Reported operating income collapsed 96% to $11 million and diluted earnings per share fell to $0.00. Exclude the write-off, the associated contingent-consideration reversal and other items, and core diluted earnings per share rose 11% to $0.84, core operating income grew 17% to $574 million, and core operating margin climbed to 20.6% from 19.1%. The quarter the headline called a wash is, on the company's own core basis, one of the strongest in years.
The businesses did their jobs. Surgical sales grew 8% on new equipment - the Unity platform led Equipment/other up 26% - and Vision Care sales rose 8%, with the dry-eye portfolio (Tryptyr, Systane) lifting Ocular health 13%. Gross margin jumped to 60.2% from 53.9%. The currency was a mild tailwind, and management used the momentum to do something it has rarely done this year: raise guidance. The full-year core operating-margin outlook was lifted to plus 90 to plus 190 basis points and core diluted EPS growth was raised to plus 12% to plus 15%, while net-sales growth held at plus 5% to plus 7%. Combined with a fresh $1.5 billion buyback authorization started in May - about $1.2 billion still outstanding as of June 30 - the quarter reads as operating acceleration plus capital returns, obscured by one very large, non-cash, explicitly one-time charge. The stock closed the earnings day at $75.35, up about 2% on the print.
The central question the quarter answers is whether the core beat is durable or a mirage built on easy prior-year comparisons and one-time tariff refunds. The prior-year quarter was depressed by a product discontinuation and higher inventory costs, so the margin expansion is partly a base effect. The tariff refund management expects in the third quarter (roughly $60 million, two-thirds to be reinvested) is non-recurring. The reassurance is operational: core operating income rose on manufacturing efficiencies and price, and the pipeline that failed did so loudly and was fully written down, with no cash impact on the business. This was a quarter with two stories - one a write-down, one a beat - and the market chose to read the beat.